Thomas Steyer’s Cellectis CLLS Stock Holding History

Thomas Steyer’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-385,000	Closed	-$11M	–	82
2017 Q3	$11M	Buy	+385,000	New	+$9.96M	0.1%	69

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Thomas Steyer's CLLS Position: Q4 2017 in Review

Thomas Steyer sold out of Cellectis (CLLS) in Q4 2017, closing a stake of 385,000 shares — an estimated $11M sold.

Thomas Steyer first reported a position in CLLS in Q3 2017 and held it in 1 quarter. The position peaked at $11M in Q3 2017. 57 funds tracked by Wall St. Rank hold CLLS as of Q4 2017.

Thomas Steyer reported no remaining Cellectis position as of Q4 2017 after selling out during the quarter.
Thomas Steyer sold 385,000 Cellectis shares in Q4 2017, an estimated $11M.
Thomas Steyer first reported a position in Cellectis in Q3 2017 and held it in 1 quarter.
Thomas Steyer's Cellectis position peaked at $11M in Q3 2017.
57 funds tracked by Wall St. Rank held Cellectis as of Q4 2017.

Based on Farallon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.